PALISADE BIO, INC. Shareholders' Equity
PALISADE BIO, INC. (PALI) had Shareholders' Equity of $121.75 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-10
- 2026-06-30: Stockholders' Equity Attributable to Parent $121.75M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $127.36M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $129.38M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $3.21M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $121.75M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $127.36M 10-Q · filed 2026-08-10 | |
| 2025-12-31 | $129.38M 10-Q · filed 2026-08-10 | |
| 2025-09-30 | $3.21M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $2.62M 10-Q · filed 2026-08-10 | |
| 2025-03-31 | $5.33M 10-Q · filed 2026-08-10 | |
| 2024-12-31 | $7.49M 10-Q · filed 2026-08-10 | |
| 2024-09-30 | $6.61M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $9.95M 10-Q · filed 2025-11-10 | |
| 2024-03-31 | $10.06M 10-Q · filed 2025-08-11 | |
| 2023-12-31 | $11.31M 10-K · filed 2026-03-20 | |
| 2023-09-30 | $14.08M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $15.80M 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $13.75M 10-Q · filed 2024-08-12 | |
| 2022-12-31 | $12.48M 10-K · filed 2025-03-24 | |
| 2022-09-30 | $12.43M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $4.21M 10-Q · filed 2023-11-09 | |
| 2022-03-31 | $4.79M 10-Q · filed 2023-08-10 | |
| 2021-12-31 | $7.37M 10-K · filed 2024-03-26 | |
| 2021-09-30 | $3.92M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | -$9.44M 10-Q · filed 2022-11-14 | |
| 2021-03-31 | -$20.06M 10-Q · filed 2022-08-15 | $7.73M 10-Q · filed 2021-05-14 |
| 2020-12-31 | -$16.60M 10-K · filed 2023-03-22 | $9.77M 10-K · filed 2021-03-22 |
| 2020-09-30 | -$12.85M 10-Q · filed 2021-11-12 | $14.12M 10-Q · filed 2020-11-10 |
| 2020-06-30 | -$11.68M 10-Q · filed 2021-11-12 | $16.23M 10-Q · filed 2020-08-13 |
| 2020-03-31 | -$10.23M 10-Q · filed 2021-08-23 | $9.98M 10-Q · filed 2020-05-15 |
| 2019-12-31 | -$8.33M 10-K · filed 2022-03-17 | $5.13M 10-K · filed 2020-03-27 |
| 2019-09-30 | $7.04M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $1.96M 10-Q · filed 2020-11-10 | |
| 2019-03-31 | $3.27M 10-Q · filed 2020-11-10 | |
| 2018-12-31 | $6.05M 10-K · filed 2021-03-22 | |
| 2018-09-30 | $4.48M 10-Q · filed 2019-11-14 | |
| 2018-06-30 | $6.18M 10-Q · filed 2019-11-14 | |
| 2018-03-31 | $6.61M 10-Q · filed 2019-11-14 | |
| 2017-12-31 | $8.52M 10-K · filed 2020-03-27 | |
| 2017-09-30 | $11.56M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $7.69M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $9.78M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $11.33M 10-K · filed 2019-03-22 | |
| 2016-09-30 | -$3.78M 10-Q · filed 2016-11-08 | |
| 2016-06-30 | $836.49K 10-Q · filed 2016-08-11 | |
| 2016-03-31 | -$169.39K 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $4.97M 10-K · filed 2018-04-02 | |
| 2015-09-30 | $8.90M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $14.54M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $19.36M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $17.72M 10-K · filed 2017-03-23 | |
| 2014-09-30 | $20.90M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $24.03M 10-Q · filed 2014-08-08 | |
| 2014-03-31 | $26.90M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $8.42M 10-K · filed 2016-03-14 | |
| 2013-09-30 | $8.27M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $4.41M 10-Q · filed 2013-08-08 | |
| 2013-03-31 | $5.69M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $6.97M 10-K · filed 2016-03-14 | |
| 2012-09-30 | $9.10M 10-Q · filed 2012-11-09 | |
| 2012-06-30 | $2.49M 10-Q · filed 2012-08-09 | |
| 2012-03-31 | $4.53M 10-Q · filed 2012-05-09 | |
| 2011-12-31 | $1.66M 10-K · filed 2015-03-16 | |
| 2011-09-30 | $3.90M 10-Q · filed 2011-11-09 | |
| 2011-06-30 | $6.27M 10-Q/A · filed 2011-09-23 | |
| 2010-12-31 | $7.85M 10-K · filed 2014-03-10 | |
| 2009-12-31 | -$5.02M 10-K · filed 2012-03-30 | |
| 2008-12-31 | -$2.56M 10-K · filed 2012-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |